Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. O'Kane GM, et al. Among authors: bradbury pa. Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Lung Cancer. 2017. PMID: 28577943 Review.
Chemotherapy and surgery for operable NSCLC.
Bradbury PA, Shepherd FA. Bradbury PA, et al. Lancet. 2007 Jun 9;369(9577):1903-4. doi: 10.1016/S0140-6736(07)60715-6. Lancet. 2007. PMID: 17544498 No abstract available.
A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. Bradbury PA, et al. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11. doi: 10.1158/1055-9965.EPI-07-0470. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18199725 Clinical Trial.
Immunotherapy for lung cancer.
Bradbury PA, Shepherd FA. Bradbury PA, et al. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S164-70. doi: 10.1097/JTO.0b013e318174e9a7. J Thorac Oncol. 2008. PMID: 18520304 Free article. Review.
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ Jr, Christiani DC, Liu G. Cescon DW, et al. Among authors: bradbury pa. Clin Cancer Res. 2009 May 1;15(9):3103-9. doi: 10.1158/1078-0432.CCR-08-3120. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383811 Free PMC article.
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.
Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G. Bradbury PA, et al. Clin Cancer Res. 2009 Jul 15;15(14):4680-5. doi: 10.1158/1078-0432.CCR-09-0192. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584152 Free PMC article.
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. Bradbury PA, et al. Pharmacogenet Genomics. 2009 Aug;19(8):613-25. doi: 10.1097/FPC.0b013e32832f3010. Pharmacogenet Genomics. 2009. PMID: 19620936 Free PMC article.
124 results